KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short term Debt (2019 - 2020)

Historic Short term Debt for Nektar Therapeutics (NKTR) over the last 5 years, with Q1 2020 value amounting to $254.1 million.

  • Nektar Therapeutics' Short term Debt changed N/A to $254.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $254.1 million, marking a year-over-year change of. This contributed to the annual value of $252.9 million for FY2019, which is N/A changed from last year.
  • Latest data reveals that Nektar Therapeutics reported Short term Debt of $254.1 million as of Q1 2020.
  • In the past 5 years, Nektar Therapeutics' Short term Debt ranged from a high of $254.1 million in Q1 2020 and a low of $252.9 million during Q4 2019